Journal of Ophthalmology / 2020 / Article / Tab 2

Research Article

Effects of Oral Vitamin B1 and Mecobalamin on Dry Eye Disease

Table 2

Comparison of pre- and posttreatment in each group.

Group 1Group 2Group 3Group 4
B12B12B12B12

Signs (mean ± SD)TMH (mm)0.18 ± 0.050.20 ± 0.070.21 ± 0.070.16 ± 0.060.18 ± 0.070.17 ± 0.070.18 ± 0.050.17 ± 0.060.18 ± 0.070.17 ± 0.050.19 ± 0.060.18 ± 0.07
TBUTF (s)5.19 ± 2.655.23 ± 2.205.85 ± 2.604.70 ± 1.804.87 ± 2.376.12 ± 3.814.21 ± 1.214.89 ± 1.805.31 ± 2.07#3.98 ± 1.804.55 ± 1.625.10 ± 2.74
TBUTA (s)6.60 ± 2.857.06 ± 2.157.55 ± 3.285.93 ± 1.796.15 ± 2.157.55 ± 3.28∂#5.70 ± 1.716.46 ± 1.486.44 ± 2.335.09 ± 1.975.95 ± 1.956.71 ± 2.78
CNFD (mm/mm2)14.14 ± 2.8416.56 ± 1.7617.51 ± 1.0513.47 ± 1.1413.33 ± 1.9314.36 ± 1.616.54 ± 1.859.71 ± 2.4913.93 ± 2.59#7.11 ± 2.4810.55 ± 2.1215.98 ± 1.72#

Symptoms (mean ± SD, scores)Dryness5.13 ± 3.416.03 ± 3.035.83 ± 3.616.15 ± 3.145.58 ± 2.925.70 ± 2.796.15 ± 3.076.43 ± 3.544.69 ± 3.30∂#5.88 ± 3.134.47 ± 3.324.64 ± 3.03
Foreign body sensation3.70 ± 3.704.88 ± 3.474.88 ± 3.403.38 ± 3.613.30 ± 3.073.98 ± 3.365.38 ± 3.645.30 ± 3.433.42 ± 3.41∂#4.66 ± 3.763.47 ± 3.793.59 ± 3.57
Pain1.95 ± 3.001.50 ± 2.612.00 ± 2.882.65 ± 3.182.75 ± 2.972.83 ± 3.033.63 ± 3.182.80 ± 3.302.04 ± 2.864.03 ± 3.612.53 ± 3.293.82 ± 3.57
Burning1.15 ± 1.861.65 ± 2.771.45 ± 2.732.25 ± 3.182.40 ± 2.992.93 ± 2.742.10 ± 3.182.33 ± 3.340.96 ± 1.97#2.47 ± 3.651.44 ± 2.331.27 ± 2.90
Watering2.10 ± 2.922.50 ± 3.102.48 ± 3.032.30 ± 3.042.28 ± 3.042.33 ± 2.784.05 ± 3.593.33 ± 3.873.73 ± 3.541.94 ± 3.152.16 ± 3.332.00 ± 3.27
Asthenopia4.50 ± 3.805.30 ± 3.075.10 ± 3.395.75 ± 3.466.23 ± 2.955.75 ± 3.205.65 ± 3.226.00 ± 3.224.96 ± 3.374.31 ± 3.763.97 ± 3.345.23 ± 3.19
Blurred vision3.55 ± 3.562.20 ± 3.123.60 ± 3.51#3.10 ± 3.623.45 ± 3.043.20 ± 3.433.13 ± 3.492.85 ± 3.423.81 ± 3.373.97 ± 4.042.81 ± 3.413.41 ± 3.59
Itching2.85 ± 2.892.60 ± 2.473.15 ± 2.982.15 ± 3.452.25 ± 3.103.48 ± 3.232.98 ± 3.333.23 ± 3.182.58 ± 3.202.59 ± 3.261.88 ± 2.651.91 ± 2.86
Increased secretions1.25 ± 2.811.05 ± 2.631.23 ± 1.821.35 ± 2.722.48 ± 3.452.20 ± 2.592.43 ± 3.612.48 ± 3.223.27 ± 2.993.66 ± 3.533.28 ± 3.742.73 ± 3.38
Photophobia3.40 ± 3.823.95 ± 3.743.33 ± 3.594.80 ± 3.694.90 ± 3.644.03 ± 3.295.00 ± 3.824.63 ± 3.933.54 ± 3.39#4.84 ± 3.903.75 ± 3.673.68 ± 3.71
Total29.58 ± 17.9731.33 ± 14.6732.95 ± 19.7033.88 ± 12.8835.60 ± 17.4736.40 ± 15.3840.48 ± 21.4539.35 ± 20.7332.73 ± 23.3338.34 ± 23.6729.75 ± 23.0732.27 ± 25.31

Satisfaction (mean ± SD, scores)Before4.00 ± 2.633.60 ± 2.993.82 ± 2.604.50 ± 2.404.22 ± 2.504.20 ± 2.564.41 ± 2.973.40 ± 2.192.82 ± 1.303.29 ± 2.593.60 ± 2.173.50 ± 3.13
After5.21 ± 2.625.72 ± 2.215.67 ± 2.326.05 ± 2.145.87 ± 2.626.27 ± 2.104.67 ± 1.675.31 ± 3.03
After-before1.43 ± 2.391.89 ± 1.971.44 ± 1.921.85 ± 1.392.47 ± 2.653.45 ± 2.240.50 ± 1.772.00 ± 2.18
Following advice9.07 ± 2.338.94 ± 2.188.83 ± 1.448.50 ± 1.559.53 ± 1.289.55 ± 0.809.86 ± 0.369.29 ± 1.20
Improvement6.00 ± 3.115.56 ± 3.166.28 ± 3.196.80 ± 2.896.33 ± 2.777.36 ± 2.326.57 ± 2.345.86 ± 3.90

B: baseline; 1: 1 month; 2: 2 months; TMH: tear meniscus height; TBUTF: tear film breakup time first; TBUTA: tear film breakup time average; CNFD: corneal nerve fiber density. Satisfaction: before: pretreatment satisfaction with ocular surface; after: posttreatment satisfaction with ocular surface; following advice: compliance with the doctor's advice; improvement: satisfaction with therapeutic effects. values of less than 0.05 were considered statistically significant and are expressed as 1 month versus baseline, #2 months versus baseline, and 2 months versus 1 month in the same group.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.